{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:52:19Z","timestamp":1791388339759,"version":"4.3.3"},"reference-count":56,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Guangdong Provincial Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ymthe.2026.01.037","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:48:05Z","timestamp":1771919285000},"page":"3417-3435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Anti-CD19-engineered exosomes enable B cell-targeted anti-BAFF mRNA delivery to alleviate lupus progression"],"prefix":"10.1016","volume":"34","author":[{"given":"Linda","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxian","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuping","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4829-8390","authenticated-orcid":false,"given":"Xi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.01.037_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102615","article-title":"Clinical disease activity and flare in SLE: Current concepts and novel biomarkers","volume":"119","author":"Thanou","year":"2021","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.ymthe.2026.01.037_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2478\/rir-2020-0009","article-title":"2020 Chinese Guidelines for the Diagnosis and Treatment of Systemic Lupus Erythematosus","volume":"1","author":"Li","year":"2020","journal-title":"Rheumatol. Immunol. Res."},{"key":"10.1016\/j.ymthe.2026.01.037_bib3","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1007\/s10147-024-02611-2","article-title":"Current status of BAFF targeting immunotherapy in B-cell neoplasm","volume":"29","author":"Tagami","year":"2024","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.01.037_bib4","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/art.40396","article-title":"Abnormal B Cell Development in Systemic Lupus Erythematosus: What the Genetics Tell Us","volume":"70","author":"Karrar","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.ymthe.2026.01.037_bib5","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/ard-2022-223741","article-title":"Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets","volume":"82","author":"Crow","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ymthe.2026.01.037_bib6","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrrheum.2014.33","article-title":"The BAFF\/APRIL system in SLE pathogenesis","volume":"10","author":"Vincent","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ymthe.2026.01.037_bib7","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/imr.12810","article-title":"BAFF inhibition in SLE-Is tolerance restored?","volume":"292","author":"Jackson","year":"2019","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ymthe.2026.01.037_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102736","article-title":"B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE)","volume":"20","author":"M\u00f6ckel","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.ymthe.2026.01.037_bib9","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.3389\/fimmu.2018.02285","article-title":"BAFF and BAFF-Receptor in B Cell Selection and Survival","volume":"9","author":"Smulski","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.01.037_bib10","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.136417","article-title":"Effects of B cell-activating factor on tumor immunity","volume":"5","author":"Yarchoan","year":"2020","journal-title":"JCI insight"},{"key":"10.1016\/j.ymthe.2026.01.037_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030491","article-title":"Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus","volume":"3","author":"Bauer","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.ymthe.2026.01.037_bib12","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/cei.12975","article-title":"Associations of B cell-activating factor (BAFF) and anti-BAFF autoantibodies with disease activity in multi-ethnic Asian systemic lupus erythematosus patients in Singapore","volume":"189","author":"Howe","year":"2017","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ymthe.2026.01.037_bib13","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ymthe.2026.01.037_bib14","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.01.037_bib15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2017-211631","article-title":"A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea","volume":"77","author":"Zhang","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ymthe.2026.01.037_bib16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12967-019-1804-8","article-title":"How mRNA therapeutics are entering the monoclonal antibody field","volume":"17","author":"Van Hoecke","year":"2019","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.01.037_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202202771","article-title":"Nebulized mRNA-Encoded Antibodies Protect Hamsters from SARS-CoV-2 Infection","volume":"9","author":"Vanover","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ymthe.2026.01.037_bib18","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.ymthe.2019.05.012","article-title":"mRNA Delivery for Therapeutic Anti-HER2 Antibody Expression In Vivo","volume":"27","author":"Rybakova","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.01.037_bib19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.ymthe.2026.01.037_bib20","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12951-023-02044-5","article-title":"Emerging non-viral vectors for gene delivery","volume":"21","author":"Wang","year":"2023","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.ymthe.2026.01.037_bib21","article-title":"Targeted exosome-mediated delivery of opioid receptor Mu siRNA for the treatment of morphine relapse","volume":"5","author":"Liu","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2026.01.037_bib22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41551-019-0485-1","article-title":"Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation","volume":"4","author":"Yang","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2026.01.037_bib23","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41467-018-03733-8","article-title":"Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson's disease treatment","volume":"9","author":"Kojima","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.01.037_bib24","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1021\/acs.molpharmaceut.5b00071","article-title":"CD19-Targeted Nanodelivery of Doxorubicin Enhances Therapeutic Efficacy in B-Cell Acute Lymphoblastic Leukemia","volume":"12","author":"Krishnan","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ymthe.2026.01.037_bib25","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.01.037_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12404","article-title":"Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches","volume":"13","author":"Welsh","year":"2024","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.ymthe.2026.01.037_bib27","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic Lupus Erythematosus: A Review","volume":"331","author":"Siegel","year":"2024","journal-title":"Jama"},{"key":"10.1016\/j.ymthe.2026.01.037_bib28","article-title":"Belimumab for systemic lupus erythematosus","volume":"2","author":"Singh","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ymthe.2026.01.037_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003981","article-title":"Analysis of belimumab prescription and outcomes in a 10-year monocentric cohort: is there an advantage with early use?","volume":"10","author":"Tani","year":"2024","journal-title":"RMD open"},{"key":"10.1016\/j.ymthe.2026.01.037_bib30","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13075-025-03581-0","article-title":"Enhancing systemic lupus erythematosus treatment outcomes with an early initiation of belimumab: insights from a multicenter retrospective study within the first five years","volume":"27","author":"Kojima","year":"2025","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.ymthe.2026.01.037_bib31","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/S0140-6736(24)00398-2","article-title":"Systemic lupus erythematosus","volume":"403","author":"Hoi","year":"2024","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ymthe.2026.01.037_bib32","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1093\/eurheartj\/ehae883","article-title":"Extracellular vesicle-mediated VEGF-A mRNA delivery rescues ischaemic injury with low immunogenicity","volume":"46","author":"You","year":"2025","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ymthe.2026.01.037_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2024-001296","article-title":"Belimumab versus telitacicept in sequential treatment after rituximab for refractory lupus nephritis: a real-world multicentre study","volume":"12","author":"Chen","year":"2025","journal-title":"Lupus Sci. Med."},{"key":"10.1016\/j.ymthe.2026.01.037_bib34","article-title":"Therapeutic Potential of Lipid Nanoparticle-Encapsulated CD19-Targeting mRNAs in Lupus and Rheumatoid Arthritis","volume":"12","author":"Guo","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ymthe.2026.01.037_bib35","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/art.39503","article-title":"MEDI-551 Treatment Effectively Depletes B Cells and Reduces Serum Titers of Autoantibodies in Mice Transgenic for Sle1 and Human CD19","volume":"68","author":"Gallagher","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.ymthe.2026.01.037_bib36","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1016\/j.apsb.2024.06.024","article-title":"A rationally designed CD19 monoclonal antibody-triptolide conjugate for the treatment of systemic lupus erythematosus","volume":"14","author":"Wang","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ymthe.2026.01.037_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202417205","article-title":"Localized Delivery of the mRNAs Encoding CD47 Inhibitor and Interleukins 12, 15, and 21 Elicits Robust Antitumor Immunity","volume":"12","author":"Jiang","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ymthe.2026.01.037_bib38","doi-asserted-by":"crossref","first-page":"8042","DOI":"10.1038\/s41467-023-43798-8","article-title":"A lung-selective delivery of mRNA encoding broadly neutralizing antibody against SARS-CoV-2 infection","volume":"14","author":"Tai","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.01.037_bib39","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","article-title":"Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus","volume":"18","author":"Jin","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ymthe.2026.01.037_bib40","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1038\/s41591-025-03937-8","article-title":"Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial","volume":"31","author":"Feng","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.01.037_bib41","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ymthe.2026.01.037_bib42","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41392-025-02262-3","article-title":"Clinical investigation on nebulized human umbilical cord MSC-derived extracellular vesicles for pulmonary fibrosis treatment","volume":"10","author":"Li","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2026.01.037_bib43","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1097\/DCR.0000000000003502","article-title":"Localized Administration of Mesenchymal Stem Cell-Derived Exosomes for the Treatment of Refractory Perianal Fistula in Patients With Crohn's Disease: A Phase II Clinical Trial","volume":"67","author":"Hadizadeh","year":"2024","journal-title":"Dis. Colon Rectum"},{"key":"10.1016\/j.ymthe.2026.01.037_bib44","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12943-020-01278-3","article-title":"Exosome-based immunotherapy: a promising approach for cancer treatment","volume":"19","author":"Xu","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ymthe.2026.01.037_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103291","article-title":"Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases","volume":"148","author":"Zeng","year":"2024","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.ymthe.2026.01.037_bib46","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2026.01.037_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122256","article-title":"An efficient approach for SARS-CoV-2 monoclonal antibody production via modified mRNA-LNP immunization","volume":"627","author":"Hsu","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ymthe.2026.01.037_bib48","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2019.04.006","article-title":"A review of bispecific antibodies and antibody constructs in oncology and clinical challenges","volume":"201","author":"Suurs","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ymthe.2026.01.037_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14630","article-title":"Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge","volume":"8","author":"Pardi","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.01.037_bib50","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1515\/rir-2024-0029","article-title":"Therapeutic potential of CD20\/CD3 bispecific antibodies in the treatment of autoimmune diseases","volume":"5","author":"Huang","year":"2024","journal-title":"Rheumatol. Immunol. Res."},{"key":"10.1016\/j.ymthe.2026.01.037_bib51","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.3390\/curroncol30070467","article-title":"Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management","volume":"30","author":"Markouli","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ymthe.2026.01.037_bib52","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","article-title":"Bispecific antibodies: advancing precision oncology","volume":"10","author":"Herrera","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ymthe.2026.01.037_bib53","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/s41565-023-01404-4","article-title":"Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines","volume":"18","author":"Han","year":"2023","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ymthe.2026.01.037_bib54","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.str.2004.02.033","article-title":"Molecular basis of box C\/D RNA-protein interactions; cocrystal structure of archaeal L7Ae and a box C\/D RNA","volume":"12","author":"Moore","year":"2004","journal-title":"Structure (London, England : 1993)"},{"key":"10.1016\/j.ymthe.2026.01.037_bib55","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/rheumatology\/keh656","article-title":"Induction of systemic lupus erythematosus-like syndrome in syngeneic mice by immunization with activated lymphocyte-derived DNA","volume":"44","author":"Qiao","year":"2005","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.ymthe.2026.01.037_bib56","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/s41590-022-01310-2","article-title":"Genetic dissection of TLR9 reveals complex regulatory and cryptic proinflammatory roles in mouse lupus","volume":"23","author":"Leibler","year":"2022","journal-title":"Nat. Immunol."}],"updated-by":[{"DOI":"10.1016\/j.ymthe.2026.08.040","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000}},{"DOI":"10.1016\/j.ymthe.2026.08.040","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000}}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626000808?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626000808?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T12:20:56Z","timestamp":1788178856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626000808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1525001626000808"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.01.037","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-CD19-engineered exosomes enable B cell-targeted anti-BAFF mRNA delivery to alleviate lupus progression","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.01.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}